Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
Globe Newswire•16/11/2026•07:00 ET
0
Key Highlights
- ➤FDA grants Cardiff Oncology (CRDF) Fast Track designation for onvansertib in first-line RAS-mutated mCRC
- ➤30 mg onvansertib regimen posts 72.2% confirmed objective response rate
- ➤Response rate improves 30 points versus FOLFIRI/bevacizumab alone at 42.1%
- ➤Median progression-free survival not reached versus approximately 11 months for standard care
- ➤Cardiff plans registrational trial of onvansertib plus FOLFIRI/bevacizumab
Expert Statements
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need.”
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“Our randomized Phase 2 data give us confidence that onvansertib may provide an additive benefit to the current standard-of-care, as reflected in the maturing data from the ongoing trial.”
Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology
“We look forward to working closely with the FDA as we advance onvansertib into our planned registrational trial and bringing this potential new treatment option to patients as quickly as possible.”
Designation covers onvansertib in combination with FOLFIRI/bevacizumab for adult patients with KRAS- or NRAS-mutated mCRC
The designation is supported by clinical data from the ongoing randomized, controlled CRDF-004 clinical trial
Get started
Create a free account to read the full story.
